Semtech Innovates in the Smart Home and Healthcare Industries with Next-Generation IoT Solution
May 18, 2017 12:05 pm UTC| Business
CAMARILLO, Calif., May 18, 2017 -- Semtech Corporation (Nasdaq:SMTC), a leading supplier of analog and mixed-signal semiconductors, announced its collaboration with Movtek, a leading developer of Internet of Things...
Semtech Innovates in the Smart Home and Healthcare Industries with Next-Generation IoT Solution
May 18, 2017 12:05 pm UTC| Business
CAMARILLO, Calif., May 18, 2017 -- Semtech Corporation (Nasdaq:SMTC), a leading supplier of analog and mixed-signal semiconductors, announced its collaboration with Movtek, a leading developer of Internet of Things...
Semtech Innovates in the Smart Home and Healthcare Industries with Next-Generation IoT Solution
May 18, 2017 12:05 pm UTC| Business
CAMARILLO, Calif., May 18, 2017 -- Semtech Corporation (Nasdaq:SMTC), a leading supplier of analog and mixed-signal semiconductors, announced its collaboration with Movtek, a leading developer of Internet of Things...
Semtech Innovates in the Smart Home and Healthcare Industries with Next-Generation IoT Solution
May 18, 2017 12:05 pm UTC| Business
CAMARILLO, Calif., May 18, 2017 -- Semtech Corporation (Nasdaq:SMTC), a leading supplier of analog and mixed-signal semiconductors, announced its collaboration with Movtek, a leading developer of Internet of Things...
Albireo Announces Plans for Phase 3 Clinical Program of A4250 in Patients with PFIC
May 18, 2017 12:05 pm UTC| Business
— Program design finalized following consultations with FDA and EMA — — Initiation of Phase 3 anticipated in the second half of 2017 — BOSTON, May 18, 2017 -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage...
Albireo Announces Plans for Phase 3 Clinical Program of A4250 in Patients with PFIC
May 18, 2017 12:05 pm UTC| Business
— Program design finalized following consultations with FDA and EMA — — Initiation of Phase 3 anticipated in the second half of 2017 — BOSTON, May 18, 2017 -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage...
Albireo Announces Plans for Phase 3 Clinical Program of A4250 in Patients with PFIC
May 18, 2017 12:05 pm UTC| Business
— Program design finalized following consultations with FDA and EMA — — Initiation of Phase 3 anticipated in the second half of 2017 — BOSTON, May 18, 2017 -- Albireo Pharma, Inc. (Nasdaq:ALBO), a clinical-stage...
India's 2025 Trade Push: Major FTAs & Global Partnerships Secured